Neurocrine Biosciences, Inc. (NBIX) Q2 2010 Earnings Results

Neurocrine Biosciences Beats on EPS, Stock Down 2.85%

Neurocrine Biosciences reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock fell by 2.85% following the earnings report, likely due to the lack of revenue data and no updated guidance. This suggests that investors may be cautious about the company's near-term outlook despite the EPS beat.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.09	N/A	+47.98%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management acknowledged the difficulties faced in the current environment. They remain focused on strategic initiatives to drive future growth.

Management highlighted ongoing challenges in the market.

They expressed commitment to long-term growth despite current setbacks.

Neurocrine Biosciences Beats on EPS, Stock Down 2.85%

Key numbers

Management commentary

Neurocrine Biosciences, Inc.

More earnings this week

Neurocrine Biosciences Beats on EPS, Stock Down 2.85%

Key numbers

Management commentary